Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
14 February 2012Website:
http://www.organovo.comNext earnings report:
07 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 9 min agoDividend
Analysts recommendations
Institutional Ownership
ONVO Latest News
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The meeting was held November 15-19, 2024 in San Diego, California.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, by Dr. Eric Lawitz of the Texas Liver Institute, will describe the findings from the FXR314 Phase 2 MASH study. The meeting will be held November 15-19, 2024 in San Diego, California.
Nio Inc (NYSE: NIO) opened more than 10% up on Thursday after a JPMorgan analyst issued a super bullish note in its favour. Nick Lai now sees upside in the EV stock to $8.0.
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company's near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798.
Organovo is scheduled to share information about its primary clinical-stage medication, FXR314, at DDW2024, taking place in Washington, D.C. from May 18-21, 2024.
Organovo Holdings announced on Monday that its experimental drug for a certain type of fatty liver disease achieved the primary objective in a mid-stage trial, causing its stock to rise by almost 27% in premarket trading.
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
What type of business is Organovo Holdings?
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California.
What sector is Organovo Holdings in?
Organovo Holdings is in the Healthcare sector
What industry is Organovo Holdings in?
Organovo Holdings is in the Biotechnology industry
What country is Organovo Holdings from?
Organovo Holdings is headquartered in United States
When did Organovo Holdings go public?
Organovo Holdings initial public offering (IPO) was on 14 February 2012
What is Organovo Holdings website?
https://www.organovo.com
Is Organovo Holdings in the S&P 500?
No, Organovo Holdings is not included in the S&P 500 index
Is Organovo Holdings in the NASDAQ 100?
No, Organovo Holdings is not included in the NASDAQ 100 index
Is Organovo Holdings in the Dow Jones?
No, Organovo Holdings is not included in the Dow Jones index
When was Organovo Holdings the previous earnings report?
No data
When does Organovo Holdings earnings report?
The next expected earnings date for Organovo Holdings is 07 February 2025